The United States spends far more on cancer care than other wealthy nations, but it’s not seeing a return on that investment in terms of lives saved, a new study shows.
Compared with the average high-income country, researchers found the U.S. spends twice as much on cancer care — more than $200 billion a year. Yet the nation’s cancer death rates remain just about average.
Experts said the findings — published May 27 in the journal JAMA Health Forum — are not entirely surprising. It’s well known that the U.S. pays much more for cancer drugs, for example, so the heavy spending on cancer treatment was expected.
“But it was disappointing to see that despite that, our outcomes aren’t at the top of the pack,” said senior researcher Dr. Cary Gross, a professor at Yale School of Medicine.
Why is all that spending not reaping bigger rewards?
Gross said those high drug prices are likely a big factor: If the U.S. is paying more for the same treatments, that could go a long way in explaining why its cancer death rates are no lower than many other countries’.
When it comes to approving new drugs, Gross said, “most other countries are a little more dubious than we are.”
The U.S. tends to approve more new cancer treatments more quickly than other countries — often without evidence they improve patients’ long-term survival.
Unlike the U.S., other countries consider costs when making decisions on new drug approvals, and also negotiate prices of those drugs. In contrast, new cancer drugs typically have a higher starting price in the U.S., and that price tag usually grows over time, Gross and his colleagues point out.
That happens, in large part, because Medicare, which provides health insurance to older Americans, has no power to negotiate drug prices.
Beyond that, Gross said, Americans with cancer tend to receive more aggressive treatment — sometimes getting chemotherapy in the last months of life, when it does not make a difference in survival.
Dr. William Dahut, chief scientific officer for the American Cancer Society, made similar points. Cancer drugs cost more in the U.S., he said, and a large portion of spending goes toward patients with incurable cancers.
Lengthening people’s lives and giving palliative care — treatment to manage pain and otherwise improve quality of life — are important goals, Dahut stressed. But those expenditures do not prevent deaths.
For the study, Gross and his team looked at cancer care spending and cancer death rates in 22 high-income countries for the year 2020. Overall, the U.S. spent twice as much per capita, compared with the average for all countries studied — nearly $600 per person, versus $300.
Yet cancer death rates in the U.S. were only slightly lower than the median, or midpoint, for all countries studied — about 86 deaths per 100,000 people, versus 91 per 100,000.
Even that small difference went away once researchers factored in smoking: It’s less common in the U.S. than in many other countries, which helps protect more Americans from getting certain cancers in the first place.
Overall, nine countries had lower “smoking-adjusted” cancer death rates than the U.S., despite spending less on cancer care: Australia, Finland, Iceland, Japan, Korea, Luxembourg, Norway, Spain and Switzerland.
For his part, Dahut saw a positive in those smoking-related figures.
“Smoking cessation has been critical to lowering cancer mortality in the U.S.,” he said.
While that’s true, Gross said more needs to be done on the prevention front — including addressing the nation’s high obesity rate, and improving Americans’ diet quality and physical activity levels.
Both Dahut and Gross said disparities could be playing a role in the U.S. cancer death rates, too. Studies show that Black Americans and Hispanic Americans have lower screening rates for certain cancers, and even after a cancer is detected may face delays in treatment.
“Care is much more expensive when the cancer is more advanced,” Dahut said.
Gross also pointed to the larger picture: While the U.S. spends a lot on cancer care, it generally spends less than other wealthy countries on social programs that may help people live healthier.
“We’re willing to spend the money,” he said. “But I don’t think we’re investing wisely.”
The American Cancer Society has advice on lowering cancer risk.
SOURCES: Cary Gross, MD, professor, medicine, Yale School of Medicine, New Haven, Conn.; William Dahut, MD, chief scientific officer, American Cancer Society, Atlanta; JAMA Health Forum, May 27, 2022, online
18 CommentsLeave a Reply
F*ckin¦ remarkable things here. I am very happy to look your post. Thank you a lot and i am taking a look forward to touch you. Will you kindly drop me a mail?
Super-Duper site! I am loving it!! Will come back again. I am taking your feeds also
What i don’t realize is actually how you are not actually much more well-liked than you might be now. You’re so intelligent. You realize therefore significantly relating to this subject, made me personally consider it from a lot of varied angles. Its like women and men aren’t fascinated unless it is one thing to accomplish with Lady gaga! Your own stuffs nice. Always maintain it up!
We are a group of volunteers and starting a new scheme in our community. Your web site provided us with valuable information to work on. You have done a formidable job and our entire community will be grateful to you.
I truly appreciate this post.Really looking forward to read more. Want more.
I think other website proprietors should take this web site as an model, very clean and fantastic user genial style and design, let alone the content. You are an expert in this topic!
You should take part in a contest for one of the best blogs on the web. I will recommend this site!
Super-Duper website! I am loving it!! Will be back later to read some more. I am taking your feeds also.
Some really good articles on this site, thank you for contribution. “Once, power was considered a masculine attribute. In fact, power has no sex.” by Katharine Graham.
Thank you, I’ve just been looking for info approximately this topic for a long time and yours is the greatest I’ve discovered so far. However, what in regards to the bottom line? Are you sure concerning the source?
Nice post. I was checking continuously this blog and I am impressed! Extremely useful information specifically the last part 🙂 I care for such info much. I was seeking this particular info for a long time. Thank you and good luck.
The crux of your writing while appearing agreeable originally, did not sit well with me after some time. Someplace within the paragraphs you managed to make me a believer unfortunately just for a short while. I nevertheless have a problem with your jumps in assumptions and you would do nicely to fill in those gaps. When you actually can accomplish that, I could undoubtedly be amazed.
Merely wanna admit that this is extremely helpful, Thanks for taking your time to write this.
Amazing blog! Do you have any suggestions for aspiring writers? I’m planning to start my own site soon but I’m a little lost on everything. Would you propose starting with a free platform like WordPress or go for a paid option? There are so many choices out there that I’m completely overwhelmed .. Any recommendations? Bless you!
I’m really impressed with your writing skills and also with the layout on your blog. Is this a paid theme or did you modify it yourself? Either way keep up the nice quality writing, it’s rare to see a great blog like this one these days..
Some genuinely good information, Gladiolus I observed this.
Some truly wonderful information, Glad I found this.
191366 776283Spot lets start function on this write-up, I truly believe this incredible web site requirements much more consideration. Ill apt to be once again to read a fantastic deal more, many thanks for that info. 293438